|
A word from
our President
Fall is usually a hectic season for the life sciences industry, and this year is no exception.
We recently published our 2022-2023 annual report. It summarizes the achievements of the entire adMare team over the course of the year, done in partnership with ecosystem colleagues from coast to coast to coast. As of the end of our fiscal year, adMare has helped create and support 29 portfolio companies that have attracted over $2.3 billion in investment, have a combined value of over $2.8 billion, and employ over 1000 Canadians. I invite you to consult the report to discover all the progress made over the past year by clicking here. It is worth noting that these numbers have already grown again this year.
Our Board of Directors welcomed three new members, Martin LeBlanc, co-founder, former CEO and Vice Chair of CellCarta Biosciences, Tim van Biesen, Head of Bain & Company's Global Healthcare Practice, and John DeLucchi, President and CEO of Madison Venture Corporation. The leadership of each of them will bring a fresh perspective to our activities. Our Board of 5 women and 5 men (in addition to me) provides essential guidance and counsel to our organization.
This balance reflects an important focus on inclusion, diversity, equity, and accessibility (IDEA) at adMare and in our industry. adMare recently joined forces with LSO, Shift Health and Pfizer to publish a report entitled Status of IDEA in Canada's Life Sciences Sector. I invite you to take a look at the report to see where we stand, and to discover our recommendations. More importantly, I encourage you to help us be a leader in this area – we still have a lot of work to do.
Respectfully,
Gordon C. McCauley
President and CEO, adMare BioInnovations
Building Companies
Novo Nordisk to acquire Inversago Pharma, an adMare porfolio company, to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases
Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up to 1.075 billion US dollars in cash if certain development and commercial milestones are achieved. Inversago Pharma is a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders.
Specific Biologics, an adMare porfolio company, announced additional investment and appointment of experienced biotechnology leader Steven Kanner, PhD, to the board of directors
Specific Biologics Inc. announced it has appointed Steven Kanner, PhD, as an Independent Director. Dr. Kanner joins Brent Stead, PhD, MBA, as well as seasoned company builders Daniel Hétu, MD, MBA of Lumira Ventures, Nikhil Thatte, B.Eng of Lumira Ventures and Frédéric Lemaître Auger, MSc, PhD, MBA of adMare BioInnovations. The appointment coincides with renewed investment from Lumira Ventures and adMare BioInnovations to advance the preclinical development of therapeutics based on Specific's proprietary Dualase® platform gene editors.
adMare portfolio company Zucara Therapeutics announced two positive developments
Zucara Therapeutics dosed first patient in Phase 2a 'ZONE' trial evaluating the effect of ZT-01 on preventing nighttime hypoglycemia in people with Type 1 diabetes.
Zucara Therapeutics announced additional funding from JDRF to support ZT-01 phase 2 study.
Thryv Therapeutics, an adMare portfolio company, announced FDA clearance for Phase 1 study of THRV-1257 in Anaplastic Thyroid Cancer
THRV-1257 is being investigated for the treatment of advanced Anaplastic Thyroid Cancer (ATC), including those patients with the common BRAF mutation V600E. The first in human study will determine the optimal dosing of THRV-1257 in patients with solid tumors, followed by treatment in combination with approved cancer therapies.
Thryv Therapeutics also presented in vitro and in vivo preclinical results of SGK1 inhibition in ATC models at the American Thyroid Association (ATA) Annual Meeting.
Building Ecosystems
adMare BioInnovations launched the refreshed version of the adMare Community with new engaging features
adMare BioInnovations was proud to launch the enhanced adMare Community, a revamped online platform with several new, more advanced and efficient features, dedicated to nurturing the Canadian life sciences ecosystem and harnessing the collaborative power of our community.
adMare BioInnovations and MaRS Discovery District Welcome Inaugural Ontario Start-Ups to Therapeutics Accelerator Program
adMare BioInnovations and MaRS Discovery District are pleased to welcome Quthero Canada and NorthMiRs as the first Ontario-based ventures in the MaRS-adMare Therapeutics (Tx) Accelerator.
adMare is Proud to have joined LSO, Shift Health and Pfizer in the publication of a landmark report published on the status of inclusion, diversity, equity and accessibility (IDEA) in Canada's life sciences sector
The report is informed by the findings from a national survey of life sciences organizations and focus groups with diverse individuals working in the sector. With a focus on highlighting differences between small/medium and large organizations, the report uncovers where life sciences organizations have made progress in IDEA, how IDEA initiatives have impacted individuals working in the sector, and, importantly, immediate opportunities and recommendations to guide organizations to make progress IDEA.
adMare BioInnovations celebrated LEED certification of Building 2 of the Montreal adMare Innovation Centre
The Montreal team celebrated this achievement by inviting resident companies to a networking cocktail.
LEED is the most widely used green building rating system in the world and an international symbol of excellence. Through design, construction, and operation practices that improve environmental and human health, LEED-certified buildings are helping to make the world more sustainable.
In the Media
Seizing the moment: building Canada's academic leadership into a commercial powerhouse
In this editorial published in The Hill Times, Gordon C. McCauley, President and CEO of adMare, reminds us that while Canada excels in terms of the quality of academic research, its discoveries are not leading to the creation of enough biotech companies to accelerate their commercialization.
The special life sciences edition of BIV magazine is online.
British Columbia's life sciences industry is on the move. Discover the ecosystem's strengths and industry players' views on how to continue fostering the sector's growth. Don't miss Gordon C. McCauley's perspective and adMare's article on our company creation model (page 20).
Upcoming Events
adMare Discovery Session with Brian Bloom
On November 16 at 12 p.m. ET, Brian Bloom, co-founder, CEO, and Chairman of Bloom Burton & Co, will dive deep into the past year, dissecting the investment landscape, financing trends, and the ebb and flow of risk capital within the Canadian life sciences arena (webinar).
A Look Back at Recent Events
adMare Industry Builder Series featuring Roberto Bellini
adMare was pleased to welcome Roberto Bellini, former President and CEO of Bellus Health, who spoke about how the company overcame the obstacles encountered during the development of camlipixant, a P2X3 antagonist, until its acquisition by GSK last spring.
Global Leader Series with Dr. Yoshua Bengio
adMare was honored to welcome a world trailblazer in artificial intelligence, Dr. Yoshua Bengio, Founder and Scientific Director of MILA, who demystified how artificial intelligence can be used to accelerate drug development, as well as the risks and challenges associated with the technology.
Join the adMare Community
today and you'll never miss a life sciences event again!
Building Talent
The latest cohorts of the Executive Institute and the BioInnovation
Scientist Program are underway
Cohort II of the Bioinnovation Scientist Program was launched on October 16. The 10-week program offers online training to enable early-career scientists to develop the skills they need to succeed in the Canadian life sciences industry.
The candidates of the Executive Institute's Cohort VI have been selected and will begin the program conceived to build leadership capacity among Canada's life sciences professionals. We look forward to presenting the Cohort VI's candidates.
A Final Word
adMare is pleased to welcome three new Life Sciences Leaders to its Board of Directors
Join us to welcome the arrival of Martin LeBlanc, co-founder, former CEO and Vice Chair of CellCarta Biosciences, Tim van Biesen, Head of Bain & Company's global healthcare practice, and John DeLucchi, President and CEO of Madison Venture Corporation, to adMare's Board of Directors.
adMare BioInnovations
Vancouver
2405 Wesbrook Mall
Vancouver, British Columbia, Canada
V6T 1Z3
Montreal
Montréal, Québec, Canada
H4S 1Z9
Toronto
Toronto, Ontario, Canada
M5G 1L7
 |